Document Detail


Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia.
MedLine Citation:
PMID:  15377287     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND AIM: Hepatitis C virus (HCV) infection is now the leading notifiable disease in Australia. The current study aimed to determine the prevalence of HCV and hepatitis B virus (HBV) infection and associated risk behaviors among injecting drug users (IDUs) screened in south-western Sydney as part of a multisite prospective cohort study. METHODS: Using a combination of snowball sampling and word-of-mouth recruitment strategies, 377 IDUs were interviewed using a structured questionnaire and tested for exposure to HCV and HBV. Entry criteria were injecting drug use in the previous 6 months and antibody HCV serostatus not known to be positive. RESULTS: More than one-third (36.6%) tested HCV antibody positive and one-quarter (28%) had been exposed to HBV. Independent predictors of HCV seropositivity were HBV core antibody positive serostatus, incarceration in the past year, injecting in public, Asian ethnicity and duration of injecting. Individual risk behaviors, including sharing needles and syringes, sharing other injecting equipment and being injected by others, were not significant in either bivariate or multivariate models. CONCLUSIONS: Results indicate an urgent need for structural interventions designed to reduce the exposure of IDUs, particularly indigenous Australian and Asian injectors, to risk environments. Structural interventions, including population-based hepatitis B immunization, expanded access to needle and syringe programs and drug treatment, prison diversion programs and medically supervised injecting facilities, should be incorporated into existing blood-borne virus prevention efforts.
Authors:
Lisa Maher; Kerry Chant; Bin Jalaludin; Penny Sargent
Related Documents :
7795507 - Mortality among hiv-infected intravenous drug addicts in stockholm in relation to metha...
16123687 - Requiring help injecting independently predicts incident hiv infection among injection ...
15525237 - Hepatitis c-related discrimination in new south wales.
20521407 - The effectiveness evaluation of a multimedia hepatitis c prevention program for hispani...
22581877 - Sulphadiazine-induced obstructive renal failure complicating treatment of hiv-associate...
17883997 - Considering metabolic issues when initiating hiv therapy.
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of gastroenterology and hepatology     Volume:  19     ISSN:  0815-9319     ISO Abbreviation:  J. Gastroenterol. Hepatol.     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-09-20     Completed Date:  2005-03-31     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8607909     Medline TA:  J Gastroenterol Hepatol     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  1114-20     Citation Subset:  IM    
Affiliation:
School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW, Australia. L.Maher@unsw.edu.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Australia / epidemiology
Female
Hepatitis B / diagnosis,  epidemiology*,  etiology
Hepatitis B Antibodies / blood
Hepatitis C / diagnosis,  epidemiology*,  etiology
Hepatitis C Antibodies / blood
Humans
Male
Middle Aged
Needle Sharing / statistics & numerical data
Prevalence
Prospective Studies
Risk-Taking
Substance Abuse, Intravenous / complications,  epidemiology*
Chemical
Reg. No./Substance:
0/Hepatitis B Antibodies; 0/Hepatitis C Antibodies

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hepatitis C virus and lichen planus.
Next Document:  Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in h...